Whether a Thai pesticide registration moves forward depends mostly on the dossier, not on who you know. Projects stall not because an agent is missing, but because the data was never aligned: the technical-grade specification does not match the formulator on record, the toxicology report was run on a different active-content than the formulation being registered, or the company paid for chronic studies that full registration requires while the project is still at trials clearance.
This article draws on the annex Data requirement for pesticide registration to the DOA notification on registration, together with the review practice that has held since the Hazardous Substances Act (No. 4) B.E. 2562 (2019) took effect on 27 October 2019. It explains what each of the three registration phases requires, how the phases differ, and in what order companies should prepare their data. One thing needs saying up front: the chronic toxicology requirements of Phases II and III are not applied uniformly — only products still inside their patent or data protection period are asked to add sub-acute, teratogenicity, reproductive, mutagenicity and neurotoxicity work plus residue data. For off-patent products, published data will usually stand in, and Phase II can often be skipped altogether.
1. The Framework: Three Phases, Three Data Sets
Thai pesticide registration is not a single submission. It is filed in stages, with each stage unlocking the next. DOA splits registration into three phases, each with a different purpose and a different data set:
| Phase | Purpose | Data focus |
|---|---|---|
| Phase I — Trials Clearance | Establish efficacy and acute toxicity; the clearance allows producing or importing a limited quantity of sample for efficacy or residue trials | Active ingredient identity, physico-chemical properties, acute toxicity, trial protocol |
| Phase II — Provisional Clearance | Demonstrate real-world use — centred on two years of efficacy and residue trials at two local sites; allows limited-area demonstration use. Sub-acute, teratogenicity, reproductive, mutagenicity and neurotoxicity data plus residue data are only added where the product is still within its patent or data protection period | Local efficacy and residue trial reports, full formulation phys-chem, packaging and environment (sub-chronic toxicology and residues added only for in-patent products) |
| Phase III — Full Registration | Final evaluation of all trials and data: efficacy, human and environmental safety, including long-term (2-year) chronic toxicity — long-term studies are expected mainly for new active ingredients or products still in patent | Everything in Phase II plus 2-year chronic, special studies, human data, PHI data, efficacy and residue trial reports |
One rule that is often overlooked: if the applicant already holds the complete data set required for full registration, Phase II can be skipped and full registration applied for directly. In practice this path is used most by two kinds of product: those with a mature dossier already registered in another country, and active ingredients registered in Thailand for more than ten years whose patent has long expired. For the second group, once trials clearance is in hand and the data is complete, full registration can be filed directly — saving an entire round of trials and two years of waiting.
The notification also carries an exemption: a hazardous substance produced or imported solely for export, of the same kind as a substance already registered in Thailand but with a different formulation and concentration, is exempt from the main data items of that phase (1.1–1.8 for Phase I, 2.1–2.12 for Phase II, 3.1–3.12 for Phase III). Companies doing export-oriented formulation should check whether they qualify.
2. The Dividing Line: Is Your Product Still in Patent?
This is the single most valuable point in the article: DOA tiers its chronic toxicology requirements by the patent and data-protection status of the product, not uniformly across all products. It explains a familiar pattern — two companies file for full registration, one spends three years generating toxicology and the other gets its certificate in eighteen months. The difference is rarely the agent; it is whether the product is still in patent.
| Product status | How to tell | How far the toxicology and residue data must go |
|---|---|---|
| New active ingredient (never registered in Thailand) | Not on DOA's list of registered active ingredients | Everything: acute, sub-acute, chronic (2 years), teratogenicity/reproductive/mutagenicity/neurotoxicity/carcinogenicity, metabolism, residues and environment. A ten-year data protection period runs from first registration |
| Registered active ingredient, still within patent or data protection | First registered in Thailand less than ten years ago, or the compound patent is still live | A complete technical-grade dossier is still required, including GLP sub-chronic, chronic and eco-toxicology data. The additional chronic toxicology and residue studies are mandatory at this tier |
| Off-patent, or registered in Thailand for over ten years | First registered in Thailand more than ten years ago and the patent has expired | Long-term toxicology can be met with published data: FAO/WHO specifications and evaluations, JMPR reports, EU review conclusions, US EPA re-registration documents. Sub-chronic, chronic and eco-toxicology data can be submitted on that basis rather than regenerated. Local efficacy and residue trials are still not waivable |
| Export only | Produced or imported solely for export | Exempt from the main data items of that phase where the substance is of the same kind as one already registered in Thailand and differs only in formulation and concentration |
Two dates decide which tier you fall into: the date the compound was first registered in Thailand, and whether the patent and data protection on the technical material are still live. Those two dates determine the tier, and with it the budget and schedule for the next two or three years.
One caveat: this tiering is DOA's review practice rather than a single line written into the data list. Assessors can differ on whether published data is sufficient for a given product. Assemble the published data you intend to cite, pre-judge it with your agent, and if necessary confirm with DOA in writing before you start — it is far cheaper than a deficiency letter later.
3. Phase I: The Nine Data Groups for Trials Clearance
1. Identity of the active ingredient (1.1)
Common name proposed or accepted by ISO or others, manufacturer code number, chemical name by IUPAC nomenclature, structural formula, empirical formula and molecular weight. This group looks trivial but is a common rejection point: the common name and code must be consistent across every later report, label and authorisation document.
2. Physical and chemical properties of the active ingredient (1.2)
Appearance (physical state, colour, odour); melting/decomposition/boiling point (°C); vapour pressure, preferably at 20–25 °C and only when above 10⁻³ Pascal; solubility in water and organic solvents; partition coefficient between water and a stated non-miscible solvent; density (liquids only); hydrolysis rate and photolysis under stated conditions; and spectra absorption (UV, visible, infra-red).
3. Information on the formulated product (1.3)
Trade name or manufacturer's code, plus formulator name and address; content of the active ingredient and other components (g/kg for solids, g/L for liquids) with the nature of the formulation; and the use category. Formulator name and address anchor every later document — change it once and a whole batch of documents has to be redone.
4. Physical and chemical properties of the product (1.4)
Physical state and colour; flammability (flash point for liquids, whether flammable for solids); acidity/alkalinity (pH); and other properties such as corrosiveness, evaporation and inflammation.
5. Toxicological data on the technical grade material (1.5)
Six animal studies: acute oral toxicity, acute dermal toxicity, inhalation toxicity, skin irritation, eye irritation and skin (dermal) sensitization.
6. Toxicological data on the formulated product (1.6)
The same six studies, but on the formulation being registered — technical-grade data cannot substitute for them.
7. Poisoning and first aid (1.7)
Precautions for use and storage; diagnosis of poisoning with specific signs and clinical tests; first aid measures; and medical treatment.
8. Environmental toxicity (1.8)
Information on environmental toxicity, for example fish toxicity (LC50).
9. Analytical method and trial plan (1.9)
Analytical method for the active ingredient, and one set of experimental plans for efficacy and/or residue trials. The trial protocol is a core deliverable of Phase I — once the plan is accepted, the field work has a basis to proceed.
4. What Phases II and III Add on Top
Phase I only lets you run trials. From Phase II onwards the dossier becomes a complete registration package. The additions fall into five blocks:
Technical grade material: content range and impurity profile (2.2)
- Minimum and maximum content of the active ingredient, expressed as weight/weight percentage;
- Nature and quantity of isomers, impurities, contaminants and other by-products, together with their deviations (weight/weight percentage).
This block determines whether the later toxicology and residue conclusions are accepted at all. Change the technical specification and previously completed toxicology studies may need re-evaluation.
Formulation phys-chem: from basic properties to full specification (2.5)
- Storage stability; density (liquids only);
- Particle size range;
- Persistent foam, for formulations mixed with water before use;
- Wettability, for water-mixed formulations such as WP and WG;
- Suspensibility, for WP, SC, WG and similar;
- Wet sieve test (WP, SC, WG); dry sieve test for powder and granule formulations such as DS and GR;
- Emulsion stability for EC formulations; compatibility with other compounds;
- Stability of field dilutions, in hours.
Packaging (2.6)
Type and size of containers, material used for the container, results of the corrosion test on the container, and results of storage testing in the sale container. Many companies redo this block after changing packaging supplier, because the material certificate no longer matches.
Toxicology: from acute to chronic (2.7–2.8 / 3.7–3.9)
- Added in Phase II (only for products still within their patent or data protection period; off-patent products generally substitute published data or are exempt): sub-acute studies; teratology/reproductive studies; mutagenicity studies; toxicity to the nervous system; metabolism data on absorption, excretion, distribution, accumulation and transformation with metabolites; and tumour and cancer induction, if any.
- Added in Phase III (tiered the same way, and expected mainly for new active ingredients or products still in patent): chronic studies (2 years); special toxicological studies; and human data from epidemiological, clinical or occupational studies.
Residues and the environment (2.9–2.10 / 3.10–3.11)
- Residues: principal residues (parent compound, breakdown products and metabolites) in edible crops, food or feedstuffs; the method of residue analysis, with author and type of method plus a copy of each method; residue data in crops, animal products and other food; Phase III additionally requires the data used to determine the pre-harvest interval (PHI).
- Environment — soil: persistence of residues (stating, if persistent, how many days residues likely remain after use at the recommended rate), degradation, movement in soil (nil, slight or high), and tests of effects on soil organisms.
- Environment — water: results of residue studies in water, the residue level likely to be found after use at the recommended rate, and tests on aquatic organisms other than fish; toxicity to birds, bees and fish; toxicity to other species; and the method of disposal for unwanted pesticide and containers, for example incineration at a specified temperature.
Efficacy, analytical method and foreign registrations (2.11–2.13 / 3.12–3.14)
Phase II submits the efficacy data from trials clearance; Phase III adds the efficacy data from provisional clearance and the use recommendation from the Department of Agriculture. Both phases require the analytical method consistent with the product specification, and any product registration or licence certificate from other countries.
5. Five Mistakes Companies Make Most Often
First, preparing against the full list instead of the current phase. Full registration needs 2-year chronic studies; that does not mean they are due at trials clearance — and for an off-patent product the study is not required at all. The reverse is equally costly: walking through Phase II step by step when the data is already complete adds time for nothing. Before starting, confirm which phase the project is in and what that phase's list actually is.
Second, identity fields that do not match across documents. The technical-grade manufacturer, the formulator name and address, the active ingredient content and the formulation code must read identically in the technical dossier, the formulation dossier, the letter of authorisation, the label and the certificate of free sale. Any mismatch can trigger a deficiency request. We recommend a field-by-field cross-check before submission.
Third, treating trial scheduling as something that can jump the queue. Efficacy and residue trials are constrained by crop seasons; miss a planting season and you lose a year. Field trial windows should be planned in parallel with data preparation, not after the dossier is complete. See the timeline notes in the Thai pesticide registration process for how we schedule them.
Fourth, ignoring validity and dependencies. Toxicology and residue reports carry issue dates, the analytical method must cover the specification being registered, and any change to the technical specification calls the applicability of existing toxicology conclusions into question. Treat the dossier as a set of assets that expire and depend on each other, not as a folder of PDFs.
Fifth, copying the full data list without first establishing patent status. Many companies take the complete Phase III list as their target at project kick-off and end up budgeting and scheduling two or three times what the project actually needs. The right order is to establish which tier the product falls into, then work backwards to what must be filed and when. Get the tier wrong and every downstream estimate is wrong with it.
6. Recommended Order: Map First, Fill Second
- Step 1, lock the product and the formulator. Fix the active ingredient, formulation type, content and formulator — once fixed, these fields should not move again.
- Step 2, assemble the technical-grade package. Identity and physico-chemical properties, content range and impurity profile, and the six acute toxicology studies on the technical material.
- Step 3, assemble the formulation package. Formulation information and phys-chem, packaging data, the six acute toxicology studies on the formulation, and poisoning/first-aid information.
- Step 4, schedule trials and long-lead studies. Submit the efficacy and residue protocols first, then decide whether to start the sub-chronic toxicology and residue studies at all — these take longest, but they are mandatory only for products still in patent. Spending two extra years on them for an off-patent product is one of the most common forms of waste.
- Step 5, cross-check, then submit. Verify the technical specification, formulator address, content and formulation code across every document before filing.
If you only do one thing: turn the nine Phase I data groups above into a table and mark each item as available / to be prepared / not applicable. That table will tell you the timeline, the budget, and which pieces are already in someone else's hands.
Want us to check your dossier gaps against your actual product? book a dossier review and we will return an itemised gap list with a recommended preparation order.
Related services: Thai pesticide registration agency services
Thai pesticide registration and import data
registration process and timelines